UnitedHealthcare to Use Brand-Name for Pegfilgrastim from July’19

 UnitedHealthcare to Use Brand-Name for Pegfilgrastim from July’19

UnitedHealthcare to Use Brand-Name for Pegfilgrastim from July’19

Shots:

  • United healthcare will update its preferred product coverage criteria in its White Blood Cell Colony Stimulating Factors medical drug policy i.e, it prefers the use of Neulasta Onpro and Neulasta vial over Fulphila and Udenyca
  • Additionally, UH will expand its authorization requirements on these medications intended for any diagnosis
  • For both UnitedHealthcare commercial and Community Plan members, current authorizations will be honored through their end date. The policies will be updated after authorization renewal

Click here to read full press release/ article | Ref: Center for Biosimilars | Image: UnitedHealthcare

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post